Format

Send to

Choose Destination
Neurosci Biobehav Rev. 2011 Jan;35(3):818-25. doi: 10.1016/j.neubiorev.2010.10.002. Epub 2010 Oct 12.

Evidence for GABAergic inhibitory deficits in major depressive disorder.

Author information

1
Department of Psychiatry, UT Southwestern Medical Center Dallas, 6300 Harry Hines Boulevard, Suite 1200, Dallas, TX 75390-8589, USA. paul.croarkin@utsouthwestern.edu

Abstract

Converging evidence suggests that deficits in gamma-aminobutyric acid (GABA) functioning are implicated in the pathophysiology of major depressive disorder (MDD). This is highlighted by research investigating cortical inhibition (CI), a process whereby GABAergic interneurons selectively attenuate pyramidal neurons. Transcranial magnetic stimulation (TMS) paradigms evaluate this marker of neuronal inhibitory activity in the cortex. This review will examine the neuroanatomic and neurophysiological evidence from neuroimaging, molecular, treatment, and TMS studies linking dysfunctional GABAergic neurotransmission to MDD.

PMID:
20946914
DOI:
10.1016/j.neubiorev.2010.10.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center